home ver. 2.3. site index contact us

Message from the CEO
How We Work
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Workforce Diversity
Supplier Diversity
Supplier Registration

Supplier Diversity

Overview

Schering-Plough is a globally diverse and inclusive company committed to providing equal access to procurement opportunities for qualified businesses that reflect diversity in their ownership.

Supplier diversity development is a business priority for the Company. We follow a strategic sourcing approach to identify and develop mutually beneficial working relationships with diverse suppliers certified by the Small Business Administration (SBA), National Minority Supplier Development Council (NMSDC) or Women's Business Enterprise National Council (WBENC).

To be considered for procurement opportunities, suppliers must complete the simple online registration process and meet strict business standards. These standards include excellence in product and service quality, high ethical business practices, reliability, price competitiveness and sound financial performance.

Benefits of Registering
Registration has its benefits. Registered suppliers that meet strict business standards may be:
• Considered for procurement opportunities
• Readily accessible to Schering-Plough's sourcing managers
• Included in exclusive requests for proposal
• Contacted when procurement opportunities become available  in their specific commodity or service area

For more information on Supplier Diversity and how to register, click on the following:

Supplier Diversity Glossary of Terms

Registration Process

Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough